Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10707947 | 0.98 | KDM4E (0.51) | KDM4ESMN1; SMN2ALDH1A1MAOBLOXL2 | |
| SCHEMBL15228259 | 0.87 | SMN1; SMN2 (0.56) | KDM4ESMN1; SMN2ALDH1A1LOXL2KMT2A | |
| SCHEMBL10710703 | 0.84 | SMN1; SMN2 (0.57) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL15104865 | 0.84 | L3MBTL1 (0.56) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL29679606 | 0.82 | ALDH1A1 (0.61) | KDM4ESMN1; SMN2ALDH1A1LOXL2KMT2A | |
| SCHEMBL1505656 | 0.82 | ALDH1A1 (0.61) | KDM4ESMN1; SMN2ALDH1A1LOXL2KMT2A | |
| SCHEMBL3504843 | 0.81 | MAOB (0.63) | KDM4EALDH1A1MAOBKMT2AMEN1 | |
| SCHEMBL168844 | 0.81 | MAOB (0.51) | KDM4EMAOBLOXL2KMT2AMEN1 | |
| SCHEMBL31055423 | 0.81 | SMN1; SMN2 (0.49) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL31500514 | 0.81 | KDM4E (0.58) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | KDM4E 306/4885SMN1; SMN2 3684/4885ALDH1A1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.